Wanbury informs about award of order
Pursuant to Regulation 30 (6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, Wanbury (WL) has informed the following: 1. Sertraline Form II approval received from ANVISA, BRAZIL. This is in addition to Sertraline hydrochloride Form 1 approval that Wanbury already has. WL currently hold 75% market share for sertraline in Brazil's market. Approval for Form II, will help in further consolidation company's share of business. 2. WL has received approval from one of the largest customers for a special grade of metformin. DC grade with potential business opportunity to be estimated around Rupees 15 crore per annum. Both the API manufacturing sites i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations.
The above information is a part of company’s filings submitted to BSE.
